{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:57:22Z","timestamp":1781049442755,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1245\/s10434-019-07965-w","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T13:07:45Z","timestamp":1571836065000},"page":"4673-4680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre"],"prefix":"10.1245","volume":"26","author":[{"given":"Emilia","family":"Nan Tie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumine H.","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Speakman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gyorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"7965_CR1","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u2013492.","DOI":"10.3322\/caac.21409"},{"issue":"6","key":"7965_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/bjs.4610","volume":"91","author":"AJ Hayes","year":"2004","unstructured":"Hayes AJ, Clark MA, Harries M, Thomas JM. Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg. 2004;91(6):673\u2013682.","journal-title":"Br J Surg."},{"issue":"8","key":"7965_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","volume":"12","author":"TM Pawlik","year":"2005","unstructured":"Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12(8):587\u2013596.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"7965_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/jso.2930440305","volume":"44","author":"JH Wong","year":"1990","unstructured":"Wong JH, Cagle LA, Kopald KH, Swisher SG, Morton DL. Natural history and selective management of in transit melanoma. J Surg Oncol. 1990;44(3):146\u2013150.","journal-title":"J Surg Oncol."},{"issue":"2","key":"7965_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","volume":"22","author":"RL Read","year":"2015","unstructured":"Read RL, Haydu L, Saw RP, et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2015;22(2):475\u2013481.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"7965_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","volume":"43","author":"A Testori","year":"2017","unstructured":"Testori A, Ribero S, Bataille V. Diagnosis and treatment of in-transit melanoma metastases. Eur J Surg Oncol. 2017;43(3):544\u2013560.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"7965_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1200\/JOP.18.00063","volume":"14","author":"JA Perone","year":"2018","unstructured":"Perone JA, Farrow N, Tyler DS, Beasley GM. Contemporary approaches to in-transit melanoma. J Oncol Pract. 2018;14(5):292\u2013300.","journal-title":"J Oncol Pract."},{"issue":"7","key":"7965_CR8","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","volume":"22","author":"JF Thompson","year":"2015","unstructured":"Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22(7):2135\u20132142.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"7965_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/jso.24311","volume":"114","author":"J Lippey","year":"2016","unstructured":"Lippey J, Bousounis R, Behrenbruch C, et al. Intralesional PV-10 for in-transit melanoma: a single-center experience. J Surg Oncol. 2016;114(3):380\u2013384.","journal-title":"J Surg Oncol."},{"issue":"3","key":"7965_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0360-3016(99)00066-8","volume":"44","author":"MH Seegenschmiedt","year":"1999","unstructured":"Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys. 1999;44(3):607\u2013618.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"7965_CR11","doi-asserted-by":"crossref","unstructured":"Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15(11):3003\u20133013.","DOI":"10.1245\/s10434-008-9954-6"},{"issue":"19","key":"7965_CR12","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u20131835.","journal-title":"N Engl J Med."},{"issue":"19","key":"7965_CR13","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u20131823.","journal-title":"N Engl J Med."},{"issue":"19","key":"7965_CR14","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u20131801.","journal-title":"N Engl J Med."},{"issue":"9","key":"7965_CR15","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u20131260.","journal-title":"Lancet Oncol."},{"issue":"14","key":"7965_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u20131356.","journal-title":"N Engl J Med."},{"issue":"7","key":"7965_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","volume":"36","author":"GV Long","year":"2018","unstructured":"Long GV, Eroglu Z, Infante J, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol. 2018;36(7):667\u2013673.","journal-title":"J Clin Oncol."},{"issue":"4","key":"7965_CR18","doi-asserted-by":"publisher","first-page":"e63137","DOI":"10.1371\/journal.pone.0063137","volume":"8","author":"B Weide","year":"2013","unstructured":"Weide B, Faller C, Buttner P, et al. Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. PLoS ONE. 2013;8(4):e63137.","journal-title":"PLoS One."},{"issue":"12","key":"7965_CR19","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.jid.2017.07.006","volume":"137","author":"M Gassenmaier","year":"2017","unstructured":"Gassenmaier M, Eigentler TK, Keim U, et al. Serial or parallel metastasis of cutaneous melanoma? A study of the german central malignant melanoma registry. J Invest Dermatol. 2017;137(12):2570\u20132577.","journal-title":"J Invest Dermatol."},{"key":"7965_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.","journal-title":"J Transl Med."},{"issue":"15","key":"7965_CR21","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1016\/j.ejca.2014.06.009","volume":"50","author":"AP Barbour","year":"2014","unstructured":"Barbour AP, Tang YH, Armour N, et al. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur J Cancer. 2014;50(15):2668\u20132676.","journal-title":"Eur J Cancer."},{"issue":"5","key":"7965_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1063::AID-CNCR17>3.0.CO;2-E","volume":"88","author":"XD Dong","year":"2000","unstructured":"Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer. 2000;88(5):1063\u20131071.","journal-title":"Cancer."},{"issue":"7","key":"7965_CR23","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1245\/s10434-016-5150-2","volume":"23","author":"LA Dossett","year":"2016","unstructured":"Dossett LA, Ben-Shabat I, Olofsson Bagge R, Zager JS. Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma. Ann Surg Oncol. 2016;23(7):2330\u20132335.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"7965_CR24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1245\/s10434-015-4969-2","volume":"23","author":"HM Kroon","year":"2016","unstructured":"Kroon HM, Coventry BJ, Giles MH, et al. Australian Multicenter Study of Isolated Limb Infusion for Melanoma. Ann Surg Oncol. 2016;23(4):1096\u20131103.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07965-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:04:40Z","timestamp":1603235080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07965-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7965"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07965-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"10 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Emilia Nan Tie, Lumine H. Na, Rodney J. Hicks, John Spillane, David Speakman, Michael A. Henderson, and David E. Gyorki have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}